

Tissue Source Site (TSS) Name: _____ Completed By: _____ HCMI Identifier (ID3): Completion Date (MM/DD/YYYY):


Form Notes: An Enrollment Form should be completed for each HCMI case upon qualification notice from Leidos. All information provided on this form should include activity from the Date of Initial Pathologic Diagnosis to the most recent Date of Last Contact with the patient.

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
1	ID2		2003301	Provide the patient's ID2 (this ID
				will only be used by IMS for
				internal quality control).
2	ID3		5845012	Provide the HCMI-specific
				anonymized ID (ID3).
3	Index date		6154722	Select the reference date used
				to calculate time intervals (e.g.
				days to treatment). Date of
		Initial pathologic diagnosis		initial pathologic diagnosis is
		Sample procurement		the HCMI standard and should
		First patient visit		be used unless it is unavailable.
				If an alternative index date is
				used, indicate it here and use it
Detiont Inf				for all interval calculations.
Patient Inf 4	Gender		2200604	Provide the patient's gender
4	Genuer		2200004	using the defined categories.
		Male		Identification of gender is based
		Female		upon self-report and may come
		Unspecified		from a form, questionnaire,
				interview, etc.
5	Height		649	Provide the patient's height, in
	U U			centimeters.
6	Weight		651	Provide the patient's weight, in
	-			kilograms.
7	Body mass index (BMI)		2006410	If the patient's height and
				weight are not collected,
				provide the patient's body mass
				index (BMI).
8	Race		2192199	Provide the patient's race using
				the defined categories.
				American Indian or Alaska Native:
				A person having origins in any of the original peoples of North and South
				America (including Central
				America), and who maintains tribal
				affiliation or community
				attachment.
				Asian: A person having origins in
		American Indian or Alaska Native		any of the peoples of the Far East, Southeast Asia, or in the Indian
		🗖 Asian		subcontinent including, for
		Black or African American		example, Cambodia, China, India,
		Native Hawaiian or other Pacific Islander		Japan, Korea, Malaysia, Pakistan,
		🗖 White		the Philippine Islands, Thailand, and
		Unknown		Vietnam.
		Not reported		Black or African American: A person having origins in any of the
				black racial groups of Africa.
				Native Hawaiian or other Pacific
				Islander: A person having origins on
				any of the original peoples of
				Hawaii, Guam, Samoa, or other
				Pacific Island. White: A person having origins in
				any of the original peoples of
				Europe, the Middle East, or North
				Africa.



Tissue Source Site (TSS) Name: ______ Completed By:

Question	Question Tout	Data Latry Ontions		Instruction Tout
Question 9	Question Text Ethnicity	Data Entry Options	CDE ID 2192217	Instruction Text Provide the patient's ethnicity
9	Ethnicity		2192217	using the defined categories. Hispanic or Latino: A person of
		Hispanic or Latino		Mexican, Puerto Rican, Cuban,
		Not Hispanic or Latino		Central or South American or other
		□ Unknown		Spanish culture or origin, regardless
		Not reported		of race. Not Hispanic or Latino: A person
				not meeting the definition of
				Hispanic or Latino.
10	Number of days from		3008273	Provide the number of days
	index date to date of last			from the index date to the date
	contact			of last contact.
11	Patient age on index date		6379572	Provide the age (in days) of the
				patient on the index date. <i>Note: If the patient's age is greater</i>
				than 32,872 days (90 years), please
				enter 32,872.
12	Year of birth		2896954	Provide the year of the patient's
				birth. If the patient was born prior to 1928, insert the date
				1928.
13	Family history of cancer	□ Same	5832923	Has a first-degree relative of the
		D Different		patient been diagnosed with a
		□ None		cancer of the same or a
		Unknown		different type?
14	Smoking history	Lifelong non-smoker (<100 cigarettes smoked in	2181650	Indicate the patient's history of
		a lifetime) Current smoker (includes daily and non-daily		tobacco smoking as well as their current smoking status using
		smokers)		the defined categories.
		 Current reformed smoker (duration not 		
		specified)		
		Current reformed smoker for >15 years		
		□ Current reformed smoker for ≤15 years		
15	Metastasis at diagnosis		3438571	Indicate whether there was
	assessment status	Metastatic		evidence of metastasis at the time of diagnosis of the primary
		□ Non-metastatic (confirmed)		tumor. <i>Note: If metastatic at</i>
		Non-metastatic (unconfirmed)		diagnosis, proceed to Question 16,
				otherwise, skip to Question 17.
16	Metastatic site(s) at	Lung	3029815	Indicate the site(s) of metastasis
	diagnosis			at the time of diagnosis of the
		□ Bone marrow		primary tumor. Note: If the anatomic site of tumor
		Lymph node(s)		tissue is not listed, proceed to
		Lymph node(s) - distant		Question 16a, otherwise, skip to
		Other (specify)		Question 17.
16a	Specify metastatic site(s)		3128033	If the site of metastasis is not
				included on the provided list,
				specify the site of metastasis.
Biospecime	en Information Tissue sample type(s)		2006911	Please select all the tissue
1/	collected for HCMI for	□ Normal tissue	2000911	sample types submitted for
	this case	Primary tumor		HCMI with this case.
		Metastatic		
		□ Other tissue		





ompleted E		Completion Date (MM		
Question	Question Text	Data Entry Options	CDE ID	Instruction Text
18	Number of NORMAL tissues biospecimens collected for HCMI for this case		6584256	Please provide the number of normal tissue specimens obtained for HCMI for this case. <i>Note: This number is expected to</i> <i>be 1.</i>
19	Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case		6584257	Please provide the number of primary tumor specimens obtained for HCMI for this case Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1.
20	Number of METASTATIC/RECURRENT cancer tissue biospecimens collected for HCMI model development for this case		6584258	Please provide the number of metastatic and/or recurrent cancer biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen.
21	Number of OTHER tissue biospecimens collected for HCMI model development for this case		6584259	Please provide the number of pre-malignant, non-malignant, or dysplastic tissue biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a singl site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen.
22	Total number of tissue biospecimens collected for HCMI for this case		6584271	Please provide the total number of tissue biospecimens collecte for HCMI for this case. Note: Thin number should be the sum of the normal, primary tumor, metastatic/recurrent tumor, and other biospecimen counts above.
Normal Co	ntrol Information		I	
23	Normal tissue biospecimen ordinal		6584264	Please provide a number to identify which biospecimen this is in the sequence. <i>Note: The firs</i> <i>biospecimen should be number "1,</i> <i>the second should be number "2,"</i> <i>etc.</i>



Tissue Source Site (TSS) Name: _____ Completed By: _____

Enrollment: Rhabdomyosarcoma

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
24	CMDC sample ID		6586035	Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC.
25	BPC submitter ID (if available)		6584919	Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
26	Type of normal control	 Whole blood Buccal cells Buffy coat Lymphocytes Extracted DNA from blood Extracted DNA from saliva Extracted DNA from buccal cells Extracted DNA from normal tissue FFPE non-neoplastic tissue Non-neoplastic tissue 	3081936	Indicate the type of normal control submitted for this case.
27	Anatomic site of normal tissue	 Skin Fibroadipose tissue Other (specify) Not applicable 	4132152	If non-neoplastic tissue was submitted as the normal control, select the anatomic site of the normal tissue. Note: If the anatomic site of normal tissue is not listed, proceed to Question 27a, otherwise, skip to Question 28.
27a	Other anatomic site of normal tissue		3288189	If non-neoplastic tissue, adjacent tissue, or normal tissue from another anatomic site was submitted as the normal control, provide the anatomic site of the normal tissue.
28	Distance from tumor to normal control tissue (if not blood)	 Adjacent (< or = 2cm) Distal (>2cm) Unknown Not applicable 	3088708	Indicate the distance from the site of normal tumor collection to the primary tumor. <i>Note: If</i> <i>normal tissue was not submitted,</i> <i>select 'Not applicable'.</i>
29	Normal tissue sample preservation method	Cryopreserved Cryopreserved FFPE Snap frozen Frozen	5432521	Provide the method used to preserve the normal tissue sample collected for molecular characterization.
-	ımor Biospecimen Informati			
30	ICD-10 code for primary tumor	 □ C49.0 □ C49.1 □ C49.2 □ C49.3 □ C49.4 □ C49.5 □ C49.6 □ C49.8 □ C49.9 □ Other (specify) 	3226287	Provide the ICD-10 code for the primary tumor as used to generate the ID3 for this subject. <i>Note: If the ICD-10 code is</i> <i>not listed, proceed to 30a,</i> <i>otherwise, skip to Question 31.</i>
30a	Other ICD-10 code for primary tumor		3226287	If the ICD-10 code for the tumor used to generate the model submitted to HCMI is not included on the provided list, specify the ICD-10 code.







Question	Question Text	Data Entry Options		CDE ID	Instruction Text
31	Tumor Morphology	 8902/3 (Mixed typ 8910/3 (Embryona 8912/3 (Spindle ce 8920/3 (Alveolar r 	hic rhabdomyosarcoma, NOS) e rhabdomyosarcoma) al rhabdomyosarcoma, NOS) ell rhabdomyosarcoma)	3226275	Using the patient's pathology/laboratory report, provide the ICD-O-3 histology code of the primary tumor. Note: If the ICD-O-3 histology code of the primary tumor is not listed, proceed to Question 31a, otherwise, skip to Question 32.
31a	Specify other morphology			3226275	If the ICD-O-3 histology code describing the morphology of the patient's primary tumor is not included on the previous list, provide the ICD-O-3 histology code.
32	Tissue or organ of origin	 Abdominal cavity Bladder Head and neck Limb Prostate Retroperitoneum Testes Other (specify) 		3427536	Using the patient's pathology/laboratory report, select the primary site of the disease. Note: If the primary site of the disease is not listed, proceed to Question 32a, otherwise skip to Question 33.
32a	Other tissue or organ of origin	 Abdomen Accessory sinus Adrenal gland Anus Appendix Bladder Bone Breast Connective, subcutaneous and other soft tissues Esophagus Eye Gallbladder Gum Head, face or neck Heart Kidney Larynx Lip Liver Lung Lymph node Male genital organs Mediastinum Meninges Mouth Nasal cavity Nasopharynx Oropharynx 	 Other ill-defined sites Ovary Palate Pancreas Penis Peripheral nerves and autonomic nervous system of trunk Peritoneum Pharynx Pituitary gland Prostate gland Rectosigmoid junction Renal pelvis Retroperitoneum Skin Small intestine Spinal cord Spleen Stomach Testis Thymus Thyroid gland Tongue Tonsil Trachea Unknown primary Urinary system Uterus Vagina Vulva 	3427536	If the primary site of the disease is not included on the previous list, provide the primary site of the disease.



Enrollment: Rhabdomyosarcoma Tissue Source Site (TSS) Name: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
33	Histological Type		3081932	Select the surgical pathology
		 Rhabdomyosarcoma Other (specify) 		text description of the histological tumor type. Note: If the histological tumor type is not listed, proceed to Question 33a, otherwise, skip to Question 34.
33a	Other histological type		3294805	If the traditional surgical pathology text description of the histological tumor type is not included on the previous list, please specify the histological type.
34	Histological subtype	 Alveolar Embryonal Other Unknown 	5153032	Using the patient's pathology/laboratory report, select the histological subtype of the primary tumor.
35	Prior malignancy (of the same cancer type)	Yes No Unknown	5832924	Indicate whether the patient has a history of prior malignancy of the same cancer type.
36	Prior malignancy (other cancer type)	Yes No Unknown	5878828	Indicate whether the patient has a history of prior malignancy of a different cancer type.
37	Tumor stage	 1: Favorable site 2: Unfavorable site; <= 5cm; no regional node involvement 3: Unfavorable site; > 5 cm; and/or regional node involvement 4: Metastatic disease 	5162089	Provide the stage of the tumor using the IRS (Intergroup Rhabdomyosarcoma Study) staging guidelines.
38	Intergroup Rhabdomyo- sarcoma Study group	 I: Tumor completely removed IIa: Microscopic residual; margin positive; nodes negative IIb: Microscopic residual; margin negative; nodes positive (completely resected) IIc: Microscopic residual; margin positive; nodes positive (completely resected) III: Gross residual IV: Metastasis Unknown 	4925522	Indicate the post-surgical procedure neoplasm status by IRS group.
39	Children's Oncology Group risk group	High Low Intermediate Unknown	2963688	Indicate the soft-tissue sarcoma histologic grade.
40	Was tumor confined to organ of origin?	 Yes No Unknown Not applicable 	4925494	Indicate whether the tumor was confined to the organ of origin. If T1 (confined to anatomic site of origin), please select "Yes." If T2 (extension and/or fixative to surrounding tissue), please select "No."
41	Anaplasia	Absent Focal Diffuse Unknown	4925534	Indicate whether anaplasia was present in the primary tumor.
42	Maximum diameter (cm) of primary tumor if identifiable at initial diagnosis		62602	Provide the length of the largest diameter of the primary tumor, in centimeters.



Tissue Source Site (TSS) Name: _____ Completed By: _____

HCMI Identifier (ID3):

ssue Source Site (TSS) Name: ompleted By:		HCMI Identifier (ID3): Completion Date (MM/DD/YYYY):		6113
Question	Question Text	Data Entry Options	CDE ID	Instruction Text
43	FOXO1 fusion result	 FOXO1 rearranged (FOXO1 with unknown partner) PAX3 – FOXO1 translocation PAX7 – FOXO1 translocation Other FOXO1 translocation (FOXO1 with known partner) No FOXO1 rearrangement Indeterminate 	5159111	If the histologic subtype of the primary tumor is alveolar, selec the FOXO1 gene fusion, if identified.
Primary Tu	mor Sample Information	T		1
44	Are you submitting a primary tumor tissue sample for this case?	□ Yes □ No		If yes, proceed to question 45. If submitting a metastatic/recurrent tumor sample, proceed to Question 71.
45	Primary tumor biospecimen ordinal		6584265	Please provide a number to identify which biospecimen this is in the sequence. Note: This number should be "1".
46	CMDC sample ID		6586035	Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC.
47	BPC submitter ID (if available)		6584919	Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
48	Sample represents primary diagnosis?	□ Yes □ No	6584730	Does this primary tumor specimen represent the PRIMARY DIAGNOSIS for this Case ID3? Note: If no, continue to Question 49, otherwise, skip to Question 50.
49	Specify the ICD-10 code		3226287	Provide the ICD-10 code for the primary tumor used to generate the model submitted to HCMI.
50	Tumor tissue sample preservation method	 Cryopreserved FFPE Frozen OCT Snap frozen 	5432521	Provide the method used to preserve the tumor tissue sample collected for molecular characterization.
51	Anatomic Site of tumor from which Model was Derived	Abdominal cavity Lymph node Ascites Orbit Biliary tract/liver Parameningeal Bladder Pleura Bone Prostate Bone marrow Retroperitoneum Head and neck (non-PM) Other (specify) Limb Lung	4214629	Select the anatomic site of the tumor tissue sample used to generate the model for HCMI. Note: If the tissue or organ of origin is not listed, proceed to Question 51a. Otherwise, skip to Question 52.
51a	Other anatomic site from which the tumor was obtained		5946219	If not provided in the previous list, provide the anatomic site o the tumor tissue sample used to generate the model for HCMI.

V1.0

Enrollment: Rhabdomyosarcoma



Tissue Source Site (TSS) Name: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
52	Method of cancer sample		3103514	Provide the procedure
52	procurement	Core needle biopsy	5105514	performed to obtain the
	procurement	Excisional bionsy Incisional biopsy		primary tumor tissue. <i>Note: If</i>
		□ Fine needle □ Other (marif.)		the method of procurement is not
		aspiration Dther (specify)		listed, proceed to Question 52a,
				otherwise, skip to Question 53.
52a	Specify the other method		2006730	Specify the procedure
	of tumor sample			performed to obtain the
	procurement			primary tumor tissue, if not
				included in the previous list.
53	Number of days from		3288495	Provide the number of days
	index date to date of			from the index date to the date
	tumor sample			of the procedure that produced
	procurement			the tumor tissue submitted for
				HCMI.
54	Tumor tissue type	Primary D NOS	3288124	Provide the primary tumor
		Additional Primary		tissue type for this sample.
	mor Model Information			
55	Primary model		6594596	Please provide a number to
	biospecimen ordinal			identify which biospecimen this
				is in the sequence. Note: This number is expected to be "1".
56	CMDC model ID		6586036	Please provide the CMDC model
50	CMDC model iD		0380030	ID for this sample as it will
				appear on tubes and the
				Sample Submission Form
				transmitted to the BPC.
57	BPC submitter ID (if		6584919	Please provide the BPC-
57	available)		0001010	generated ID for this sample as
				it will appear on the Sample
				Submission Form transmitted to
				the BPC.
58	Model represents		6584730	Does this MODEL represent the
	primary diagnosis?	□ Yes		PRIMARY DIAGNOSIS for this
	- , 0	□ No		Case ID3?
59	Model's primary tumor		6586035	Enter the CMDC Sample ID of
	tissue CMDC sample ID			the PRIMARY TUMOR TISSUE
				from which this model is
				derived.
60	Model's primary tumor		6584265	Enter the biospecimen ordinal
	biospecimen ordinal			of the PRIMARY TUMOR TISSUE
				from which this model is
				derived.
Treatment	Information		•	
61	History of neoadjuvant	□ No	3382737	Indicate whether the patient
	treatment	Yes; radiation prior to resection		received neoadjuvant radiation
		Yes; pharmaceutical treatment prior to		or pharmaceutical treatment.
		resection		Note: Pharmaceutical therapy is
		Yes; both radiation and pharmaceutical		addressed in Questions 63-68.
		treatment prior to resection		Radiation therapy is addressed in Questions 69-70.
62	Neoadjuvant	Cytotoxic chemotherapy	5832928	Select all neoadjuvant
	chemotherapy type	□ Hormonal		chemotherapy types that were
		Immunotherapy (cellular and immune		administered to the patient.
		checkpoint)		Note: Cytotoxic chemotherapy is
		□ Targeted therapy (small molecule inhibitors and		addressed in Questions 63-64.
		targeted antibodies)		Immunotherapy is addressed in Questions 65-66. Targeted therapy
		□ Not applicable		is addressed in Questions 67-68.
		· ·	I	15 4441 C35C4 III QUESLIOIIS 07-00.



Tissue Source Site (TSS) Name: _____

Question	Question Text	Data Entry Options		CDE ID	Instruction Text
63	Neoadjuvant chemotherapeutic regimen	 Doxorubicin Ifosfamide and Etoposide Irinotecan Temozolomide Vincristine Vinorelbine Vincristine, actinomycin-D, cyclophosphamide (VAC) Vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide (VDC/IE) 	 Vincristine, actinomycin-D, cyclophosphamide, vincristine, irinotecan (VAC/VI) Ifosfamide, carboplatin, etoposide (ICE) Vincristine, irinotecan, temozolomide (VIT) High-dose methotrexate, doxorubicin, cisplatin (MAP) Other (specify) Chemotherapy not given 	2853313	Select all chemotherapeutics used for neoadjuvant therapy. Note: If neoadjuvant chemotherapy was not given, skip to Question 65. If the neoadjuvant chemotherapeutic regimen is not listed, proceed to Question 63a, otherwise, skip to Question 64.
63a	Other neoadjuvant chemotherapeutic regimen		-	62694	If the neoadjuvant therapy is not included in the provided list, specify neoadjuvant therapies administered.
64	Days to neoadjuvant chemotherapy treatment from index date		-	5102411	Provide the number of days from index date to the date of treatment with neoadjuvant chemotherapy.
65	Immunotherapy name, specify			2185614	Specify the name of the immunotherapy administered. Note: If immunotherapy was not given, skip to Question 67.
66	Days to immunotherapy treatment from index date		-	5102411	Provide the number of days from the index date to the date of treatment with immunotherapy.
67	Targeted Therapy	 Temsirolimus Other (specify) 		6005154	Select the targeted therapy administered to the patient. Note: If targeted therapy was not given, skip to Question 69. If the targeted therapy is not listed, proceed to Question 67a, otherwise, skip to Question 68.
67a	Specify targeted therapy		-	4308476	Provide the name of the targeted therapy administered to the patient.
68	Days to targeted therapy treatment from index date		-	5102411	Provide the number of days from the index date to the date of treatment with targeted therapy.
69	Radiation therapy administered type	 2D conventional 3D conformal Brachytherapy HDR Brachytherapy LDR IMRT Proton Beam 	 Stereotactic Body RT Stereotactic Radiosurgery WBRT Other (specify) Unspecified Not applicable 	3028890	Provide the type of radiation therapy that was administered to the patient. <i>Note: If radiation</i> <i>therapy was not administered,</i> <i>proceed to Question 71. If the</i> <i>radiation therapy is not listed,</i> <i>proceed to Question 69a,</i> <i>otherwise, skip to Question 70.</i>
69a	Other radiation therapy		-	2195477	If the radiation therapy type is not included in the provided list, specify the type.



Tissue Source Site (TSS) Name: ______

Enrollment: Rhabdomyosarcoma

Question	Question Text	Data Entry Options		CDE ID	Instruction Text
70	Days to radiation treatment from index date			5102411	Provide the number of days from the index date to the date of treatment with radiation
	uale				therapy.
Metastatio	/Recurrent Tumor Biospecin	nen Information			
71	Are you submitting a metastatic/recurrent tumor tissue sample?	□ Yes □ No			Indicate whether a metastatic/ recurrent tumor biospecimen was collected for this ID3 case. Note: If yes, proceed to Question 72. If submitting an OTHER tissue sample, proceed to Question 129.
72	Metastatic/recurrent tissue biospecimen ordinal			6584266	Please provide a number to identify which biospecimen this is in the sequence. Note: The first biospecimen should be number "1", the second should be number "2", etc.
73	CMDC tissue ID			6586035	Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC.
74	BPC submitter ID (if available)			6584919	Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
75	Metastatic/ recurrent tumor tissue sample preservation method	 Cryopreserved FFPE Frozen OCT Snap frozen 		5432521	Provide the method used to preserve the metastatic/recurrent tumor tissue sample collected for molecular characterization.
76	Number of days from index date to date of diagnosis of metastasis/ recurrence			6132218	Provide the number of days from the index date to the date of diagnosis of metastatic/recurrent disease.
77	Method of metastatic/ recurrent cancer sample procurement	 Core needle biopsy Excisional biopsy Fine needle aspiratio Incisional biopsy Tumor resection Other (specify) 	n	6587389	Indicate the procedure performed to obtain the metastatic/recurrent tumor tissue. Note: If the method of procurement is not listed, proceed to Question 77a, otherwise, skip to Question 78.
77a	Other method of cancer sample procurement			6587390	If the procedure performed to obtain the tumor tissue is not included in the provided list, specify the procedure.
78	Number of days from index date to date of metastatic/ recurrent sample procurement			3288495	Provide the number of days from the index date to the date of the procedure that produced the metastatic/recurrent tumor tissue submitted for HCMI.
79	Metastatic/recurrent site	 Abdominal cavity Ascites Biliary tract/liver Bladder Bone Head and neck (non-PM) 	 Pleura Prostate Retroperitoneum Testis Lung Bone Bone marrow 	6587394	Select the site from which the metastatic/recurrent tissue used to develop the model was derived. Note: If the metastatic/recurrent site is not listed, proceed to Question 79a, otherwise, skip to Question 80.



Tissue Source Site (TSS) Name: ______ Completed By: _____

		Limb Lymph node Orbit Parameningeal	 Lymph node(s) Lymph node(s) - distant Other (specify) 		
79a	Other metastatic/ recurrent site	 Abdomen Accessory sinus Adrenal gland Anus Appendix Bladder Bone Breast Connective, subcutaneous and other soft tissues Esophagus Eye Gallbladder Gum Head, face or neck Heart Kidney Larynx Lip Liver Lung Lymph node Male genital organs Mediastinum Meninges Mouth Nasal cavity Narvous system Oropharynx 	 Other ill-defined sites Ovary Palate Pancreas Penis Peripheral nerves and autonomic nervous system of trunk Peritoneum Pharynx Pituitary gland Prostate gland Rectosigmoid junction Renal pelvis Retroperitoneum Skin Small intestine Spinal cord Spleen Stomach Testis Thyroid gland Tongue Tonsil Trachea Unknown primary Uterus Vagina Vulva 	6587395	If not included in the previous list, specify the site from which the metastatic/recurrent tissue used to develop the model was derived.
80	Site of relapse	 Local Regional Distant Not applicable 		2002506	If the primary tumor relapsed, provide the site of relapse.
81	ICD-10 code			3226287	Provide the ICD-10 code for the metastatic/recurrent tumor used to generate the model submitted to HCMI.
82	ICD-O-3 histology code			3226275	Provide the ICD-O-3 histology code describing the morphology of the metastatic/recurrent tumor used to generate the model submitted to HCMI.
83	Maintenance and/or consolidation therapy administered prior to collection of metastatic/ recurrent tissue			6119066	Provide the name(s) of the maintenance and/or consolidation therapy administered to the patient prior to the collection of the metastatic/recurrent tissue used to develop the model.



Tissue Source Site (TSS) Name: _ Completed By: _____

Enrollment: Rhabdomyosarcoma

ompleted E		Completion Date (MM/DD/YYYY):	· · · · · · ·		
Question	Question Text	Data Entry Options	CDE ID	Instruction Text	
84	Days to start of maintenance and/or consolidation therapy from index date		5102411	Provide the number of days from the index date to the date maintenance and/or consolidation therapy started.	
85	Days to last known administration date of maintenance and/or consolidation therapy from index date		5102431	Provide the number of days from the index date to the last known date of maintenance and/or consolidation therapy.	
86	Is the patient still receiving treatment?		6379568	Indicate whether the patient is still undergoing maintenance and/or consolidation therapy.	
87	Disease status	 No evidence of disease Progressive disease Stable disease Unknown 	2188290	Provide the disease status following maintenance and/or consolidation therapy.	
88	Tumor stage	 1: Favorable site 2: Unfavorable site; <= 5cm; no regional node involvement 3: Unfavorable site; > 5 cm; and/or regional node involvement 4: Metastatic disease 	5162089	Provide the stage of the tumor using the IRS (Intergroup Rhabdomyosarcoma Study) staging guidelines.	
89	Intergroup Rhabdomyo- sarcoma Study group	 I: Tumor completely removed IIa: Microscopic residual; margin positive; nodes negative IIb: Microscopic residual; margin negative; nodes positive (completely resected) IIc: Microscopic residual; margin positive; nodes positive (completely resected) III: Gross residual IV: Metastasis Unknown 	4925522	Indicate the post-surgical procedure neoplasm status by IRS group.	
90	Children's Oncology Group risk group	□ High □ Low □ Intermediate □ Unknown	2963688	Indicate the soft-tissue sarcoma histologic grade.	
91	Was tumor confined to organ of origin?	Yes No Vnknown Not applicable	4925494	Indicate whether the tumor was confined to the organ of origin. If T1 (confined to anatomic site of origin), please select "Yes." If T2 (extension and/or fixative to surrounding tissue), please select "No."	
92	Anaplasia	Absent Focal Diffuse Unknown	4925534	Indicate whether anaplasia was present in the primary tumor.	
93	Maximum diameter (cm) of primary tumor if identifiable at initial diagnosis		62602	Provide the length of the larges diameter of the primary tumor, in centimeters.	
94	FOXO1 fusion result	 FOXO1 rearranged (FOXO1 with unknown partner) PAX3 - FOXO1 translocation PAX7 - FOXO1 translocation Other FOXO1 translocation (FOXO1 with known partner) No FOXO1 rearrangement Indeterminate 	5159111	If the histologic subtype of the primary tumor is alveolar, selec the FOXO1 gene fusion, if identified.	

Tissue Source Site (TSS) Name: ______ Completed By: _____




Question	Question Text	Data Entry Options	CDE ID	Instruction Text
		or Biospecimen Information (if applicable)		
95	Are you submitting an additional metastatic/ recurrent tumor tissue sample?	□ Yes □ No		A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question</i> <i>96, otherwise, skip to Question</i> <i>119.</i>
96	Metastatic/recurrent tissue biospecimen ordinal		6584266	Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc.
97	CMDC tissue ID		6586035	Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC.
98	BPC submitter ID (if available)		6584919	Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
99	Metastatic/ recurrent tumor tissue sample preservation method	 Cryopreserved FFPE Frozen OCT Snap frozen 	5432521	Provide the method used to preserve the metastatic/ recurrent tumor tissue sample collected for molecular characterization.
100	Number of days from index date to date of diagnosis of additional metastasis/ recurrence		6132218	Provide the number of days from the index date to the date of diagnosis of additional metastatic/recurrent disease.
101	Method of metastatic/ recurrent cancer sample procurement	 Core needle biopsy Excisional biopsy Fine needle aspiration Incisional biopsy Tumor resection Other (specify) 	6587389	Indicate the procedure performed to obtain the metastatic/recurrent tumor tissue. Note: If the method of procurement is not listed, proceed to Question 101a, otherwise, skip to Question 102.
101a	Other method of cancer sample procurement		6587390	If the procedure performed to obtain the tumor tissue is not included in the provided list, specify the procedure.
102	Number of days from index date to date of metastatic/ recurrent sample procurement		3288495	Provide the number of days from the index date to the date of the procedure that produced the metastatic/recurrent tumor tissue submitted for HCMI.



Tissue Source Site (TSS) Name: _ Completed By:

Completed By: Completion Date (MM/DD/YYYY):					
Question	Question Text	Data Entry Options		CDE ID	Instruction Text
103	Metastatic/ recurrent site	 Abdominal cavity Ascites Biliary tract/liver Bladder Bone Head and neck (non-PM) Limb Orbit Parameningeal Abdomen 	 Pleura Prostate Retroperitoneum Testis Lung Bone Bone marrow Lymph node(s) Lymph node(s) - distant Other (specify) Other ill-defined sites 	6587394	Select the site from which the metastatic/recurrent tissue used to develop the model was derived. Note: If the metastatic/recurrent site is not listed, proceed to Question 103a, otherwise, skip to Question 104.
	recurrent site	 Abdomen Accessory sinus Adrenal gland Anus Appendix Bladder Bone Breast Connective, subcutaneous and other soft tissues Esophagus Eye Gallbladder Gum Head, face or neck Heart Kidney Larynx Lip Liver Lung Lymph node Male genital organs Mediastinum Measal cavity Nasopharynx Oropharynx 	 Other ill-defined sites Ovary Palate Pancreas Peripheral nerves and autonomic nervous system of trunk Peritoneum Pharynx Pituitary gland Prostate gland Rectosigmoid junction Renal pelvis Retroperitoneum Skin Small intestine Spinal cord Spleen Stomach Testis Thymus Thyroid gland Tongue Tonsil Trachea Unknown primary Urinary system Uterus Vagina Vulva 		list, specify the site from which the metastatic/recurrent tissue used to develop the model was derived.
104	Site of relapse	 Local Regional Distant Not applicable 		2002506	If the primary tumor relapsed, provide the site of relapse.
105	ICD-10 code			3226287	Provide the ICD-10 code for the metastatic/recurrent tumor used to generate the model submitted to HCMI.
106	ICD-O-3 histology code			3226275	Provide the ICD-O-3 histology code describing the morphology of the metastatic/recurrent tumor used to generate the model submitted to HCMI.





ompleted B	у:			
Question	Question Text	Data Entry Options	CDE ID	Instruction Text
107	Maintenance and/or consolidation therapy administered prior to collection of metastatic/ recurrent tissue		6119066	Provide the name(s) of the maintenance and/or consolidation therapy administered to the patient prior to the collection of the metastatic/recurrent tissue used to develop the model.
108	Days to start of maintenance and/or consolidation therapy from index date		5102411	Provide the number of days from the index date to the date maintenance and/or consolidation therapy started.
109	Days to last known administration date of maintenance and/or consolidation therapy from index date		5102431	Provide the number of days from the index date to the last known date of maintenance and/or consolidation therapy.
110	Is the patient still receiving treatment?	Yes No Unknown	6379568	Indicate whether the patient is still undergoing maintenance and/or consolidation therapy.
111	Disease status	 No evidence of disease Progressive disease Stable disease Unknown 	2188290	Provide the disease status following maintenance and/or consolidation therapy.
112	Tumor stage	 1: Favorable site 2: Unfavorable site; <= 5cm; no regional node involvement 3: Unfavorable site; > 5 cm; and/or regional node involvement 4: Metastatic disease 	5162089	Provide the stage of the tumor using the IRS (Intergroup Rhabdomyosarcoma Study) staging guidelines.
113	Intergroup Rhabdomyo- sarcoma Study group	 I: Tumor completely removed IIa: Microscopic residual; margin positive; nodes negative IIb: Microscopic residual; margin negative; nodes positive (completely resected) IIc: Microscopic residual; margin positive; nodes positive (completely resected) III: Gross residual IV: Metastasis Unknown 	4925522	Indicate the post-surgical procedure neoplasm status by IRS group.
114	Children's Oncology Group risk group	 High Intermediate Low Unknown 	2963688	Indicate the soft-tissue sarcom histologic grade.
115	Was tumor confined to organ of origin?	 Yes No Unknown Not applicable 	4925494	Indicate whether the tumor wa confined to the organ of origin. If T1 (confined to anatomic site of origin), please select "Yes." If T2 (extension and/or fixative to surrounding tissue), please select "No."
116	Anaplasia	Absent Focal Diffuse Unknown	4925534	Indicate whether anaplasia was present in the primary tumor.
117	Maximum diameter (cm) of primary tumor if identifiable at initial diagnosis		62602	Provide the length of the larges diameter of the primary tumor in centimeters.

Tissue Source Site (TSS) Name: ______ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
118	FOXO1 fusion result	□ FOXO1 rearranged (FOXO1 with unknown	5159111	If the histologic subtype of the
		partner)		primary tumor is alveolar, selec
		PAX3 – FOXO1 translocation		the FOXO1 gene fusion, if
				<u> </u>
		PAX7 – FOXO1 translocation		identified.
		Other FOXO1 translocation (FOXO1 with known		
		partner)		
		No FOXO1 rearrangement		
		□ Indeterminate		
Motastati	/ c/Recurrent Tumor Model Inj			
119	METASTATIC/		6594587	Please provide a number to
119	•		0394387	
	RECURRENT model			identify which biospecimen thi
	biospecimen ordinal			is in the sequence. Note: The fir
				biospecimen should be number "1
				the second should be number "2,"
				etc.
120	CMDC model ID		6586036	Please provide the CMDC mod
				ID for this sample as it will
				appear on tubes and the
				Sample Submission Form
				transmitted to the BPC.
121	PDC submitter ID /if		6584919	
121	BPC submitter ID (if		6584919	Please provide the BPC-
	available)			generated ID for this sample a
				it will appear on the Sample
				Submission Form transmitted
				to the BPC.
122	Model's METASTATIC/		6586035	Enter the CMDC Sample ID of
122			0580035	
	RECURRENT tumor tissue			the METASTATIC/RECURRENT
	CMDC sample ID			tissue from which this model is
				derived.
123	Model's METASTATIC/		6584266	Enter the biospecimen ordinal
	RECURRENT tumor tissue		000.200	of the METASTATIC/RECURREN
				-
	biospecimen ordinal			tissue from which this model is
				derived.
Additional	Metastatic/Recurrent Biosp	ecimen Tumor Model Information (if applicable)		
	-			
124	METASTATIC/		6594587	Please provide a number to
124	-		6594587	
124	METASTATIC/ RECURRENT model		6594587	identify which biospecimen th
124	METASTATIC/		6594587	identify which biospecimen th is in the sequence. <i>Note: The fin</i>
124	METASTATIC/ RECURRENT model		6594587	identify which biospecimen th is in the sequence. <i>Note: The fi</i> <i>biospecimen should be number</i>
124	METASTATIC/ RECURRENT model		6594587	identify which biospecimen th is in the sequence. Note: The fin biospecimen should be number "2," the second should be number "2,"
	METASTATIC/ RECURRENT model biospecimen ordinal		6594587	identify which biospecimen thi is in the sequence. Note: The fir biospecimen should be number "2 the second should be number "2," etc.
124	METASTATIC/ RECURRENT model			identify which biospecimen thi is in the sequence. <i>Note: The fir</i> <i>biospecimen should be number "1</i> <i>the second should be number "2,"</i> <i>etc.</i> Please provide the CMDC mod
	METASTATIC/ RECURRENT model biospecimen ordinal			identify which biospecimen thi is in the sequence. Note: The fir biospecimen should be number "1 the second should be number "2," etc. Please provide the CMDC mod ID for this sample as it will
	METASTATIC/ RECURRENT model biospecimen ordinal			identify which biospecimen thi is in the sequence. Note: The fir biospecimen should be number "2, etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the
	METASTATIC/ RECURRENT model biospecimen ordinal			identify which biospecimen thi is in the sequence. Note: The fir biospecimen should be number "2, etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form
	METASTATIC/ RECURRENT model biospecimen ordinal			identify which biospecimen th is in the sequence. Note: The fin biospecimen should be number "2, etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the
	METASTATIC/ RECURRENT model biospecimen ordinal			identify which biospecimen th is in the sequence. Note: The fin biospecimen should be number "2, etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if		6586036	identify which biospecimen th is in the sequence. Note: The fir biospecimen should be number "2," etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC-
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID		6586036	identify which biospecimen th is in the sequence. Note: The fir biospecimen should be number "2," etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC- generated ID for this sample a
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if		6586036	identify which biospecimen th is in the sequence. Note: The fir biospecimen should be number "2," etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC- generated ID for this sample a it will appear on the Sample
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if		6586036	identify which biospecimen th is in the sequence. Note: The fit biospecimen should be number "2," etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC- generated ID for this sample a it will appear on the Sample Submission Form transmitted
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if available)		6586036	identify which biospecimen thi is in the sequence. <i>Note: The fir biospecimen should be number "2,"</i> <i>etc.</i> Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if available) Model's METASTATIC/		6586036	identify which biospecimen thi is in the sequence. Note: The fir biospecimen should be number "2," etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted the BPC. Enter the CMDC Sample ID of
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if available)		6586036	identify which biospecimen thi is in the sequence. <i>Note: The fir biospecimen should be number "2,"</i> <i>etc.</i> Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if available) Model's METASTATIC/		6586036	identify which biospecimen th is in the sequence. <i>Note: The fir</i> <i>biospecimen should be number "2,"</i> <i>etc.</i> Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC- generated ID for this sample a it will appear on the Sample Submission Form transmitted the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if available) Model's METASTATIC/ RECURRENT tumor tissue		6586036	identify which biospecimen thi is in the sequence. <i>Note: The fir biospecimen should be number "2,"</i> <i>etc.</i> Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID		6586036 6584919 6586035	identify which biospecimen thi is in the sequence. Note: The fir biospecimen should be number "2," etc. Please provide the CMDC mod ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived.
125	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/		6586036	 identify which biospecimen this in the sequence. Note: The fir biospecimen should be number "2," etc. Please provide the CMDC mode ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Please provide the CMDC mode ID for this sample as it will appear on the Sample as it
125 126 127	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/ RECURRENT tumor tissue		6586036 6584919 6586035	 identify which biospecimen the is in the sequence. Note: The fir biospecimen should be number "2," etc. Please provide the CMDC mode ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC-generated ID for this sample a it will appear on the Sample Submission Form transmitted to the BPC. Please provide the CMDC mode ID for this sample a it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the METASTATIC/RECURRENT
125 126 127	METASTATIC/ RECURRENT model biospecimen ordinal CMDC model ID BPC submitter ID (if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/		6586036 6584919 6586035	 identify which biospecimen the is in the sequence. Note: The fir biospecimen should be number "2," etc. Please provide the CMDC mode ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC-generated ID for this sample a it will appear on the Sample Submission Form transmitted to the BPC. Please provide the CMDC mode ID for this sample a it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal



Tissue Source Site (TSS) Name: _____ Completed By: _____

Enrollment: Rhabdomyosarcoma

Question	Question Text	Data Entry Options		CDE ID	Instruction Text		
Other Biospecimen Information							
129	Are you submitting an OTHER tissue sample?	□ Yes □ No			Indicate whether an OTHER tissue sample (e.g. pre- malignant, non-malignant, or dysplastic tissue, etc.) was collected for HCMI for this case. <i>Note: If yes, proceed to Question</i> 130.		
130	OTHER tissue biospecimen ordinal			6584267	Please provide a number to identify which biospecimen this is in the sequence. Note: The first biospecimen should be number "1," the second should be number "2," etc.		
131	CMDC sample ID			6586035	Please provide the CMDC sample ID for this specimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC.		
132	BPC submitter ID (if available)			6584919	Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.		
133	OTHER tissue sample preservation method	CryopreservedFFPEFrozen	□ OCT □ Snap frozen	5432521	Provide the method used to preserve the OTHER tissue sample collected for molecular characterization.		
134	Other method of cancer sample procurement	 Core needle biopsy Excisional biopsy Fine needle aspiration 	 Incisional biopsy Tumor resection Other (specify) 	6587398	Provide the procedure performed to obtain the OTHER tissue. Note: If the method of procurement is not listed, proceed to Question 134a, otherwise, skip to Question 135		
134a	Specify method of OTHER tissue sample procurement			6587399	Specify the procedure performed to obtain the OTHER tissue.		
135	Number of days from index date to date of OTHER sample procurement			3288495	Provide the number of days from the index date to the date of the procedure that produced the OTHER tissue submitted for HCMI.		
136	Tissue type	Non-malignantOther (specify)		64784	Indicate the OTHER tissue type. Note: If the OTHER tissue type is not listed, proceed to Question 136a, otherwise, skip to Question 137.		
136a	Specify tissue type			64785	Specify the OTHER tissue type if not in the provided list.		
137	Anatomic site of OTHER tissue	 Abdominal cavity Ascites Biliary tract/liver Bladder Bone Bone marrow Head and neck (non-PM) Limb Lung 	 Lymph node Orbit Parameningeal Pleura Prostate Retroperitoneum Testis Other (specify) 	6696813	Select the site from which the OTHER tissue used to develop the model was derived. Note: If the OTHER tissue site is not listed, proceed to Question 137a, otherwise, skip to Question 138.		



Tissue Source Site (TSS) Name: _____ Completed By: _____

ompleted By:		Completion Date (MM/DD/YYYY):			
Question	Question Text	Data Entry Options		CDE ID	Instruction Text
137a	Specify anatomic site of OTHER tissue	 Abdomen Accessory sinus Adrenal gland Anus Appendix Bladder Bone Breast Connective, subcutaneous and other soft tissues Esophagus Eye Gallbladder Gum Head, face or neck Heart Kidney Larynx Lip Liver Lung Lymph node Male genital organs Mediastinum Meninges Mouth Nasal cavity Narvous system Oropharynx 	 Other ill-defined sites Ovary Palate Pancreas Peris Peripheral nerves and autonomic nervous system of trunk Peritoneum Pharynx Pituitary gland Prostate gland Rectosigmoid junction Renal pelvis Retroperitoneum Skin Small intestine Spinal cord Spleen Stomach Testis Thymus Thyroid gland Tonsil Trachea Unknown primary Uterus Vagina Vulva 	6584916	Specify the site of OTHER tissue, if not in the previous list.
138	ICD-10 code			3226287	Provide the ICD-10 code for the OTHER tissue used to generate the model submitted to HCMI.
139	ICD-O-3 histology code			3226275	Provide the ICD-O-3 histology code describing the morphology of the OTHER tissue used to generate the model submitted to HCMI.
	OTHER biospecimen Inform	ation (if applicable)			Indicate whether an additional
140	Are you submitting an additional OTHER tissue sample?	□ Yes □ No			Indicate whether an additional OTHER tissue sample (pre- malignant, non-malignant, or dysplastic tissue, etc.) is being submitted for HCMI for this case. <i>Note: If yes, proceed to</i> <i>Question 141. If no, proceed to</i> <i>Question 151.</i>
141	OTHER tissue biospecimen ordinal			6584267	Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc.



Tissue Source Site (TSS) Name: _____ Completed By: _____

Enrollment: Rhabdomyosarcoma

ompleted E					
Question	Question Text	Data Entry Options		CDE ID	Instruction Text
142	CMDC sample ID			6586035	Please provide the CMDC sample ID for this specimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC.
143	BPC submitter ID (if available)			6584919	Please provide the BPC- generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
144	OTHER tissue sample preservation method	 Cryopreserved FFPE Frozen OCT Snap frozen 		5432521	Provide the method used to preserve the OTHER tissue sample collected for molecular characterization.
145	Other method of cancer sample procurement	 Core needle biopsy Excisional biopsy Fine needle aspirat Incisional biopsy Tumor resection Other (specify) 		6587398	Provide the procedure performed to obtain the OTHER tissue. Note: If the method of procurement is not listed, proceed to Question 145a, otherwise, skip to Question 146.
145a	Specify method of OTHER tissue sample procurement			6587399	Specify the procedure performed to obtain the OTHER tissue.
146	Number of days from index date to date of OTHER sample procurement			3288495	Provide the number of days from the index date to the date of the procedure that produced the OTHER tissue submitted for HCMI.
147	Tissue type	 Non-malignant Other (specify) 		64784	Indicate the OTHER tissue type. Note: If the OTHER tissue type is not listed, proceed to Question 147a, otherwise, skip to Question 148.
147a	Specify tissue type			64785	Specify the OTHER tissue type if not in the provided list.
148	Anatomic site of OTHER tissue	 Abdominal cavity Ascites Biliary tract/liver Bladder Bone Bone marrow Head and neck (non-PM) Limb Lung 	 Lymph node Orbit Parameningeal Pleura Prostate Retroperitoneum Testis Other (specify) 	6696813	Select the site from which the OTHER tissue used to develop the model was derived. Note: If the OTHER tissue site is not listed, proceed to Question 148a, otherwise, skip to Question 149.
148a	Specify anatomic site of OTHER tissue	 Abdomen Accessory sinus Adrenal gland Anus Appendix Bladder Bone Breast Connective, subcutaneous and other soft tissues 	 Other ill-defined sites Ovary Palate Pancreas Penis Peripheral nerves and autonomic nervous system of trunk Peritoneum Pharynx Pituitary gland Prostate gland 	6584916	Specify the site of OTHER tissue, if not in the previous list.

L.O					
_			t: Rhabdomyosarcoma		
	ce Site (TSS) Name:		Lion Date (MM/DD/YYYY):		- C S S T
mpieted	Ву:				
		EsophagusEye	 Rectosigmoid junction Renal pelvis 		
		□ Gallbladder	□ Retroperitoneum		
		🗖 Gum	□ Skin		
		Head, face or neck	Small intestineSpinal cord		
		□ Heart	□ Spleen		
		☐ Kidney	□ Stomach		
		□ Larynx □ Lip	TestisThymus		
		Liver	Thyroid gland		
		Lung	Tongue		
		Lymph nodeMale genital	 Tonsil Trachea 		
		organs	Unknown primary		
		□ Mediastinum	Urinary system		
		MeningesMouth	UterusVagina		
		Nasal cavity	□ Vulva		
		□ Nasopharynx			
		Nervous systemOropharynx			
149	ICD-10 code			3226287	Provide the ICD-10 code for the
					OTHER tissue used to generate
150	ICD-O-3 histology code			3226275	the model submitted to HCMI. Provide the ICD-O-3 histology
130				5220275	code describing the morphology
					of the OTHER tissue used to
					generate the model submitted to HCMI.
Other Tiss	sue Model Information				·
151	OTHER tissue model			6594590	Please provide a number to
	biospecimen ordinal				identify which biospecimen this is in the sequence. <i>Note: The first</i>
					biospecimen should be number "1,"
					the second should be number "2," etc.
152	CMDC model ID			6586036	Please provide the CMDC model
					ID for this sample as it will
					appear on tubes and the Sample Submission Form
					transmitted to the BPC.
153	BPC submitter ID (if			6584919	Please provide the BPC-
	available)				generated ID for this sample as it will appear on the Sample
					Submission Form transmitted
				6506005	to the BPC.
4 - 4	Madalla OTUER **			6586035	Enter the CMDC Sample ID of
154	Model's OTHER tissue				the OTHER tissue from which
154	Model's OTHER tissue CMDC sample ID				the OTHER tissue from which this model is derived.
154 155	CMDC sample ID Model's OTHER tissue			6584267	this model is derived. Enter the biospecimen ordinal
	CMDC sample ID			6584267	this model is derived. Enter the biospecimen ordinal of the OTHER tissue from which
155	CMDC sample ID Model's OTHER tissue	nation (if applicable)		6584267	this model is derived. Enter the biospecimen ordinal
155	CMDC sample ID Model's OTHER tissue biospecimen ordinal II Other Tissue Model Inform OTHER tissue model	nation (if applicable)		6584267	this model is derived. Enter the biospecimen ordinal of the OTHER tissue from which this model is derived. Please provide a number to
155 Additiona	CMDC sample ID Model's OTHER tissue biospecimen ordinal	nation (if applicable)			this model is derived. Enter the biospecimen ordinal of the OTHER tissue from which this model is derived. Please provide a number to identify which biospecimen this
155 Additiona	CMDC sample ID Model's OTHER tissue biospecimen ordinal II Other Tissue Model Inform OTHER tissue model	nation (if applicable)			this model is derived. Enter the biospecimen ordinal of the OTHER tissue from which this model is derived. Please provide a number to



Tissue Source Site (TSS) Name: ______ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
157	CMDC model ID		6586036	Please provide the CMDC model
				ID for this sample as it will
				appear on tubes and the
				Sample Submission Form
				transmitted to the BPC.
158	BPC submitter ID (if		6584919	Please provide the BPC-
	available)			generated ID for this sample as
				it will appear on the Sample
				Submission Form transmitted to
				the BPC.
159	Model's OTHER tissue		6586035	Enter the CMDC Sample ID of
	CMDC sample ID			the OTHER tissue from which
				this model is derived.
160	Model's OTHER tissue		6584267	Enter the biospecimen ordinal
	biospecimen ordinal			of the OTHER tissue from which
				this model is derived.